The Net Margin of Trillium Therapeutics Inc (TRIL.TO) is
-39566.70%.
Net Margin measures the percentage of net income derived from total revenue after all expenses. It signals how much actual profit a company retains from its sales.
| Date |
Value |
| 2020-12-31 |
-39566.70%
|
| 2019-12-31 |
-31733.30%
|
| Ticker |
Name |
Value |
|
SNDX
|
Syndax Pharmaceuticals, Inc.
|
-165.60%
|
|
FDMT
|
4D Molecular Therapeutics Inc
|
-164.43%
|
|
NKTX
|
Nkarta, Inc.
|
-17566.67%
|
|
OCGN
|
Ocugen, Inc.
|
-1537.41%
|
|
ARCT
|
Arcturus Therapeutics Holdings Inc
|
-80.19%
|
|
PRAX
|
Praxis Precision Medicines, Inc.
|
-2137.48%
|
|
YMAB
|
Y-mAbs Therapeutics Inc
|
-33.83%
|
|
ARQT
|
Arcutis Biotherapeutics, Inc.
|
-4.29%
|
|
ATRA
|
Atara Biotherapeutics, Inc.
|
27.07%
|
|
DVAX
|
Dynavax Technologies Corp
|
9.85%
|
|
RYTM
|
Rhythm Pharmaceuticals, Inc.
|
-103.57%
|
|
STOK
|
Stoke Therapeutics, Inc.
|
-3.73%
|
|
STTK
|
Shattuck Labs Inc
|
-4880.90%
|
|
CYDY
|
Cytodyn Inc
|
-79255.64%
|
|
KROS
|
Keros Therapeutics, Inc.
|
35.65%
|
|
NWBO
|
Northwest Biotherapeutics Inc
|
-4365.89%
|
|
MRSN
|
Mersana Therapeutics Inc
|
-170.86%
|
|
ITOS
|
iTeos Therapeutics Inc
|
-384.04%
|
|
KNSA
|
Kiniksa Pharmaceuticals International, PLC
|
8.71%
|